STOCK TITAN

[Form 4] Repligen Corp Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Repligen Corp (RGEN) director Anthony Hunt exercised options and sold shares on 09/10/2025 under a documented plan. Mr. Hunt exercised a stock option to acquire 20,000 shares at an exercise price of $33.87, resulting in 20,000 newly acquired shares recorded in Table II. On the same date he sold multiple blocks of common stock under a 10(b)5-1 trading plan, with weighted-average sale prices reported at $116.34, $118.32, $119.64, $120.19, $121.42 and $122.23 for different tranches. After these transactions his direct beneficial ownership of common stock is reported as 100,743 shares and he beneficially owns 182,344 shares underlying options.

Il membro del consiglio Anthony Hunt di Repligen Corp (RGEN) ha esercitato opzioni e venduto azioni il 09/10/2025 nell'ambito di un piano documentato. Il signor Hunt ha esercitato un'opzione su azioni per acquistare 20.000 azioni a un prezzo di esercizio di 33,87$, risultando in 20.000 nuove azioni registrate nella Tavola II. Nello stesso giorno ha venduto blocchi multipli di azioni ordinarie in base a un piano di commercio 10(b)5-1, con prezzi medi ponderati di vendita riportati a 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ e 122,23$ per tranche diverse. Dopo tali operazioni la sua proprietà diretta beneficiaria di azioni ordinarie è riportata come 100.743 azioni e detiene benevolmente 182.344 azioni sottostanti alle opzioni.

El director Anthony Hunt de Repligen Corp (RGEN) ejerció opciones y vendió acciones el 09/10/2025 conforme a un plan documentado. El Sr. Hunt ejerció una opción sobre acciones para adquirir 20.000 acciones a un precio de ejercicio de 33,87$, resultando en 20.000 nuevas acciones registradas en la Tabla II. En la misma fecha vendió varios bloques de acciones ordinarias bajo un plan de negociación 10(b)5-1, con precios de venta promedio ponderados reportados de 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ y 122,23$ para diferentes tramos. Tras estas operaciones su titularidad directa de acciones ordinarias se reporta en 100.743 acciones y posee de forma beneficiosa 182.344 acciones subyacentes a opciones.

리플리젠 코퍼레이션(RGEN) 이사인 Anthony Hunt가 2025년 9월 10일 문서화된 계획에 따라 옵션을 행사하고 주식을 매도했습니다. Hunt 씨는 행사가격 33.87달러로 20,000주를 취득하기 위한 주식옵션을 행사했고, 이로써 20,000주의 신규 주식이 표 II에 기록되었습니다. 같은 날 그는 10(b)5-1 거래계획에 따라 보통주를 여러 차례 매도했으며, 각 트랜치에 대해 가중평균 매도가가 116.34달러, 118.32달러, 119.64달러, 120.19달러, 121.42달러, 122.23달러로 보고되었습니다. 이 거래 후 보유지분은 직접적 유익보유 주식이 100,743주로 보고되며, 옵션 기초 주식 182,344주를 유익하게 보유합니다.

Le administrateur d'Repligen Corp (RGEN), Anthony Hunt, a exercé des options et vendu des actions le 09/10/2025 dans le cadre d'un plan documenté. M. Hunt a exercé une option d'achat pour acquérir 20 000 actions à un prix d'exercice de 33,87$, ce qui donne lieu à 20 000 nouvelles actions enregistrées au tableau II. À la même date, il a vendu plusieurs blocs d'actions ordinaires dans le cadre d'un plan de négociation 10(b)5-1, les prix de vente moyens pondérés étant de 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ et 122,23$ pour différentes tranches. À la suite de ces opérations, sa propriété bénéficiaire directe d'actions ordinaires est déclarée à 100 743 actions et il détient bénévolement 182 344 actions sous-jacentes aux options.

Der Repligen-Konzern (RGEN) Direktor Anthony Hunt hat am 09.10.2025 Optionen ausgeübt und Aktien im Rahmen eines dokumentierten Plans verkauft. Herr Hunt hat eine Aktienoption ausgeübt, um 20.000 Aktien zum Ausübungspreis von 33,87$ zu erwerben, was zu 20.000 neu erworbenen Aktien führt, die in Tabelle II verzeichnet sind. Am selben Datum hat er nach einem Trading-Plan 10(b)5-1 mehrere Blöcke Stammaktien verkauft, mit gewichteten durchschnittlichen Verkaufspreisen von 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ und 122,23$ für verschiedene Tranchen. Nach diesen Transaktionen wird sein direkt nützige Beteiligung an Stammaktien mit 100.743 Aktien angegeben, und er besitzt zu Gunsten der Optionen 182.344 Aktien.

قام عضو مجلس إدارة شركة Repligen Corp (RGEN)، أنتوني هنت، بممارسة الخيارات وبيع أسهم في 09/10/2025 بموجب خطة موثقة. قام السيد هنت بممارسة خيار شراء أسهم لاكتساب 20,000 سهماً بسعر تنفيذ 33.87 دولاراً، مما أدى إلى تسجيل 20,000 سهماً مكتسباً حديثاً في الجدول II. في نفس التاريخ باع عدة كتل من الأسهم العادية وفقاً لخطة تداول 10(b)5-1، مع أسعار بيع مئوية موزونة حسب المتوسط كما وردت عند 116.34 دولاراً، 118.32 دولاراً، 119.64 دولاراً، 120.19 دولاراً، 121.42 دولاراً و122.23 دولاراً لشرائح مختلفة. بعد هذه المعاملات تبلغ الملكية الفعلية المباشرة من الأسهم العادية 100,743 سهماً وتملك فعلياً 182,344 سهماً مبدوءة من الخيارات.

Repligen Corp(RGEN)董事Anthony Hunt在一份有文件的计划下于2025年09月10日行使期权并出售股票。 Hunt先生行使股票期权以33.87美元的执行价购得20,000股,因此在表II中记载了20,000股新获得的股份。同日,他在一项10(b)5-1交易计划下出售了多个普通股股块,分批次的加权平均出售价格分别为116.34美元、118.32美元、119.64美元、120.19美元、121.42美元和122.23美元。完成这些交易后,他对普通股的直接受益所有权被报告为100,743股,并间接持有182,344股作为期权底层股票。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Director exercised low-strike options and executed sizable sales, leaving meaningful vested option exposure.

The filing shows an option exercise at a $33.87 strike for 20,000 shares paired with substantial open-market dispositions executed under a 10(b)5-1 plan at prices between ~$116 and ~$122. The exercise converted low-cost option economics into shares, while the sales monetized a portion of equity at multi-year high price bands. Post-transaction direct common shares are reported at 100,743 while option-based beneficial ownership totals 182,344 shares, with remaining vesting schedules disclosed.

TL;DR: Transactions appear compliant and documented; sales were conducted under a pre-established 10(b)5-1 plan.

The Form 4 discloses use of a 10(b)5-1 trading plan adopted December 9, 2024, for the reported sales and includes weighted-average prices and a commitment to provide detailed per-tranche pricing on request. The signature by an attorney-in-fact indicates the filing was executed via authorized representative. Vesting schedules for remaining option shares are explicitly stated, supporting transparency about future potential dilution or insider holdings.

Il membro del consiglio Anthony Hunt di Repligen Corp (RGEN) ha esercitato opzioni e venduto azioni il 09/10/2025 nell'ambito di un piano documentato. Il signor Hunt ha esercitato un'opzione su azioni per acquistare 20.000 azioni a un prezzo di esercizio di 33,87$, risultando in 20.000 nuove azioni registrate nella Tavola II. Nello stesso giorno ha venduto blocchi multipli di azioni ordinarie in base a un piano di commercio 10(b)5-1, con prezzi medi ponderati di vendita riportati a 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ e 122,23$ per tranche diverse. Dopo tali operazioni la sua proprietà diretta beneficiaria di azioni ordinarie è riportata come 100.743 azioni e detiene benevolmente 182.344 azioni sottostanti alle opzioni.

El director Anthony Hunt de Repligen Corp (RGEN) ejerció opciones y vendió acciones el 09/10/2025 conforme a un plan documentado. El Sr. Hunt ejerció una opción sobre acciones para adquirir 20.000 acciones a un precio de ejercicio de 33,87$, resultando en 20.000 nuevas acciones registradas en la Tabla II. En la misma fecha vendió varios bloques de acciones ordinarias bajo un plan de negociación 10(b)5-1, con precios de venta promedio ponderados reportados de 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ y 122,23$ para diferentes tramos. Tras estas operaciones su titularidad directa de acciones ordinarias se reporta en 100.743 acciones y posee de forma beneficiosa 182.344 acciones subyacentes a opciones.

리플리젠 코퍼레이션(RGEN) 이사인 Anthony Hunt가 2025년 9월 10일 문서화된 계획에 따라 옵션을 행사하고 주식을 매도했습니다. Hunt 씨는 행사가격 33.87달러로 20,000주를 취득하기 위한 주식옵션을 행사했고, 이로써 20,000주의 신규 주식이 표 II에 기록되었습니다. 같은 날 그는 10(b)5-1 거래계획에 따라 보통주를 여러 차례 매도했으며, 각 트랜치에 대해 가중평균 매도가가 116.34달러, 118.32달러, 119.64달러, 120.19달러, 121.42달러, 122.23달러로 보고되었습니다. 이 거래 후 보유지분은 직접적 유익보유 주식이 100,743주로 보고되며, 옵션 기초 주식 182,344주를 유익하게 보유합니다.

Le administrateur d'Repligen Corp (RGEN), Anthony Hunt, a exercé des options et vendu des actions le 09/10/2025 dans le cadre d'un plan documenté. M. Hunt a exercé une option d'achat pour acquérir 20 000 actions à un prix d'exercice de 33,87$, ce qui donne lieu à 20 000 nouvelles actions enregistrées au tableau II. À la même date, il a vendu plusieurs blocs d'actions ordinaires dans le cadre d'un plan de négociation 10(b)5-1, les prix de vente moyens pondérés étant de 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ et 122,23$ pour différentes tranches. À la suite de ces opérations, sa propriété bénéficiaire directe d'actions ordinaires est déclarée à 100 743 actions et il détient bénévolement 182 344 actions sous-jacentes aux options.

Der Repligen-Konzern (RGEN) Direktor Anthony Hunt hat am 09.10.2025 Optionen ausgeübt und Aktien im Rahmen eines dokumentierten Plans verkauft. Herr Hunt hat eine Aktienoption ausgeübt, um 20.000 Aktien zum Ausübungspreis von 33,87$ zu erwerben, was zu 20.000 neu erworbenen Aktien führt, die in Tabelle II verzeichnet sind. Am selben Datum hat er nach einem Trading-Plan 10(b)5-1 mehrere Blöcke Stammaktien verkauft, mit gewichteten durchschnittlichen Verkaufspreisen von 116,34$, 118,32$, 119,64$, 120,19$, 121,42$ und 122,23$ für verschiedene Tranchen. Nach diesen Transaktionen wird sein direkt nützige Beteiligung an Stammaktien mit 100.743 Aktien angegeben, und er besitzt zu Gunsten der Optionen 182.344 Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hunt Anthony

(Last) (First) (Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100

(Street)
WALTHAM MA 02453

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/10/2025 M 20,000 A $33.87 129,854 D
Common Stock 09/10/2025 S(1) 96 D $116.34 129,758 D
Common Stock 09/10/2025 S(1) 1,108 D $118.32(2) 128,650 D
Common Stock 09/10/2025 S(1) 3,262 D $119.64(3) 125,388 D
Common Stock 09/10/2025 S(1) 14,882 D $120.19(4) 110,506 D
Common Stock 09/10/2025 S(1) 7,584 D $121.42(5) 102,922 D
Common Stock 09/10/2025 S(1) 2,179 D $122.23(6) 100,743 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $33.87 09/10/2025 M 20,000 (7) 03/01/2028 Common Stock 20,000 $0.00 182,344 D
Explanation of Responses:
1. Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024.
2. $118.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.80 to $118.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. $119.64 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.83 to $119.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. $120.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.85 to $120.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
5. $121.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.86 to $121.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
6. $122.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.92 to $122.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
7. 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027.
/s/ Jennifer Carmichael (Attorney in Fact) 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Repligen director Anthony Hunt do on 09/10/2025 (RGEN)?

He exercised a stock option for 20,000 shares at a $33.87 strike and sold multiple blocks of common stock under a 10(b)5-1 plan at weighted-average prices between $116.34 and $122.23.

How many shares does Anthony Hunt beneficially own after the transactions?

The filing reports 100,743 shares of common stock beneficially owned directly and 182,344 shares underlying options after the reported transactions.

Were the sales part of a trading plan?

Yes. The sales were effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024, as disclosed in the Form 4 explanations.

What is the exercise/vesting status of the option shares?

The filing states 207,344 underlying option shares have vested; remaining option shares vest 28,777 on March 1, 2026 and 28,778 on March 1, 2027.

Who signed the Form 4 filing for Anthony Hunt?

The Form 4 is signed by Jennifer Carmichael (Attorney in Fact) on behalf of the reporting person, dated 09/11/2025.
Repligen

NASDAQ:RGEN

RGEN Rankings

RGEN Latest News

RGEN Latest SEC Filings

RGEN Stock Data

6.76B
52.50M
6.38%
99.2%
6.44%
Medical Instruments & Supplies
Biological Products, (no Disgnostic Substances)
Link
United States
WALTHAM